EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, United Therapeutics's enterprise value is $8,583 Mil.
United Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 was $875 Mil. Therefore, United Therapeutics's EV-to-EBITDA for today is 9.81.
The historical rank and industry rank for United Therapeutics's EV-to-EBITDA or its related term are showing as below:
UTHR'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -59.7 Med: 6.47 Max: 27.9
Current: 9.81
During the past 13 years, the highest EV-to-EBITDA of United Therapeutics was 27.90. The lowest was -59.70. And the median was 6.47.
UTHR's EV-to-EBITDA is ranked worse than 52.48% of 484
companies
in the Biotechnology industry
Industry Median: 8.66
vs UTHR: 9.81
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2022-08-17), United Therapeutics's stock price is $220.53.
United Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $13.210. Therefore, United Therapeutics's PE Ratio for today is 16.69.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
United Therapeutics EV-to-EBITDA Historical Data
The historical data trend for United Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
United Therapeutics Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
EV-to-EBITDA
7.09
4.45
-43.12
8.03
13.01
United Therapeutics Quarterly Data
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
EV-to-EBITDA
10.57
11.16
13.01
7.09
10.59
Competitive Comparison
For the Biotechnology subindustry, United Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, United Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where United Therapeutics's EV-to-EBITDA falls into.
United Therapeutics EV-to-EBITDA Calculation
United Therapeutics's EV-to-EBITDA for today is calculated as:
United Therapeutics's current Enterprise Value is $8,583 Mil.
United Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $875 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Therapeutics (NAS:UTHR) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
United Therapeutics's PE Ratio for today is calculated as:
United Therapeutics's share price for today is $220.53.
United Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.210.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of United Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
1.13(0.51%) Volume: 3,492 9:33AM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:UTHR has been successfully added to your 
